netFormulary Kettering General Hospital NHS
NHS Foundation Trust  
 Search
 Formulary Chapter 6: Endocrine system - Full Section
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
06.01 Drugs used in diabetes (0,0)
06.01.01 Insulins (0,0)
06.01.01.01 Short-acting insulins (2,7)
Rapid Acting Insulin Analogues (4,0)
06.01.01.02 Intermediate- and long-acting insulins (0,6)
Biphasic insulins (4,9)
Intermediate Acting Insulin (3,0)
Long Acting Insulin Analogues (7,0)
06.01.01.03 Hypodermic equipment (0,7)
Needles (0,0)
Lancets (0,0)
06.01.02 Antidiabetic drugs (0,0)
06.01.02.01 Sulphonyureas (5,10)
06.01.02.02 Biguanides (2,3)
06.01.02.03 Other antidiabetic drugs (0,1)
Alpha glucosidase inhibitors (1,0)
DPP4 inhibitors (gliptins) (2,10)
SGLT2 inhibitors (4,3)
GLP1 agonists (7,0)
Glucagon-like peptide-1 receptor agonists - once weekly (0,0)
06.01.02.07 Other antidiabetic drugs (0,0)
06.01.03 Diabetic ketoacidosis (0,0)
06.01.04 Treatment of hypoglycaemia (2,0)
Chronic hypoglycaemia (0,1)
06.01.05 Treatment of diabetic nephropathy and neuropathy (0,0)
Diabetic nephropathy (0,0)
Diabetic neuropathy (0,0)
06.01.06 Diagnostic and monitoring agents for diabetes mellitus (0,0)
Blood glucose monitoring (0,37)
Urinalysis (3,17)
Oral glucose tolerance test (0,1)
Blood glucose meters for adults with type 2 diabetes (0,0)
Blood glucose meters for children and adults with type 1 diabetes (0,0)
Blood glucose meters for patients on continuous insulin infusion pump (0,0)
Blood glucose meters for patients with dexterity problems (0,0)
Talking blood glucose meters (0,0)
06.02 Thyroid and Antithyroid drugs (0,0)
06.02.01 Thyroid hormones (3,0)
06.02.02 Antithyroid drugs (3,0)
06.03 Corticosteroids (0,0)
06.03.01 Replacement therapy (1,0)
06.03.02 Glucocorticoid therapy (10,6)
Disadvantacges of corticosteriods (0,0)
Use of corticosteriods (0,0)
Pregnancy and breastfeeding (0,0)
Administration (0,0)
Withdrawal of corticosteriods (0,0)
06.04 Sex hormones (0,0)
06.04.01 Female sex hormones and their modulators (0,0)
06.04.01.01 Oestrogens and HRT (4,39)
Hormone replacement therapy (0,0)
Ethinylestradiol (0,1)
Raloxifene (1,0)
Oestrogen only tablets (0,0)
Oestrogens and progestogen sequential combined therapy (0,0)
Continuous combined therapy (0,0)
Gonadomimetic (0,0)
Selective oestrogen modulator (0,0)
06.04.01.02 Progestogens (4,8)
06.04.02 Male sex hormones and antagonists (3,9)
Anti-androgens (3,1)
Dutasteride and finasteride (0,0)
06.04.03 Anabolic steroids (0,1)
06.04.04 Gender dysphoria (0,0)
06.05 Hypothalamic and pituitary hormones and anti-oestrogens (0,0)
06.05.01 Hypothalamic and anterior pituitary hormones and anti-oestrogens (0,0)
Anti-oestrogens (1,1)
Anterior pituitary hormones (7,12)
Gonadotrophins (0,0)
Growth Hormone (0,0)
Growth hormone receptor antagonists (0,0)
Thyrotropin (0,0)
Hypothalmic hormones (1,1)
06.05.02 Posterior pituitary hormones and antagonists (0,1)
Posterior pituitary hormones (7,1)
Antidiuretic hormone antagonists (0,1)
06.06 Drugs affecting bone metabolism (0,1)
Osteoporosis (0,0)
06.06.01 Calcitonin and parathyroid hormone (0,3)
06.06.02 Bisphosphonates and other drugs affecting bone metabolism (0,0)
Bisphosphonates (10,10)
Denosumab (2,0)
Strontium renelate (0,1)
06.07 Other endocrine drugs (0,0)
06.07.01 Bromocriptine and other dopaminergic drugs (1,3)
06.07.02 Drugs affecting gonadotrophins (0,6)
Gonadorelin analogues (3,3)
Breast pain (mastalgia) (0,0)
06.07.03 Metyrapone (1,0)
06.07.04 Somatomedins (0,0)
netFormulary